益生菌:用还是不用?这就是问题
本文为社论,分析Schnadower等对两项随机安慰剂对照试验的二次分析,显示鼠李糖乳杆菌GG及L. rhamnosus R0011与L. helveticus R0052组合在主要终点中重度胃肠炎症状上与安慰剂无差异。社论另举罗伊氏乳杆菌DSM 17938系统综述及肠易激综合征荟萃分析,强调益生菌疗效具菌株特异性,需足够把握度的随机对照试验确定菌种、菌株、剂量及疗程。
要点
- 鼠李糖乳杆菌GG及特定组合菌在中重度胃肠炎症状主要终点上与安慰剂无差异。
- 益生菌疗效具菌株特异性,罗伊氏乳杆菌DSM 17938可缩短腹泻及住院时间。
- 肠易激综合征相关综述一致认为需足够把握度的随机对照试验明确菌种、菌株、剂量及疗程。
核心结论
- 益生菌临床常用且处方频繁,但部分产品缺乏强证据且经济负担高。
- 益生菌疗效具菌株特异性,需足够把握度的随机对照试验确定最优菌种、菌株、剂量及疗程。
研究设计与样本
- 社论分析Schnadower等对两项随机安慰剂对照试验的二次分析,评估鼠李糖乳杆菌GG及L. rhamnosus R0011与L. helveticus R0052组合。
- 另引用罗伊氏乳杆菌DSM 17938的随机安慰剂对照试验系统综述及肠易激综合征益生菌综述与荟萃分析。
主要发现
- 两项随机安慰剂对照试验二次分析显示,中重度胃肠炎症状主要终点在益生菌与安慰剂间无差异。
- 罗伊氏乳杆菌DSM 17938系统综述发现该益生菌缩短腹泻持续时间及住院时间。
- 肠易激综合征益生菌综述与荟萃分析结论一致:需足够把握度的随机对照试验确定菌种、菌株、剂量及疗程。
临床怎么用
- 临床处方益生菌时应关注特定菌株的证据,而非泛指益生菌类别。
- 对缺乏足够把握度随机对照试验支持的益生菌产品,应审慎评估其经济负担与临床获益。
局限性
- 社论指出益生菌常缺乏药品监管机构审批,但未涉及具体监管条款。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Editorial analyzes the paper by Schnadower et al on the secondary analysis of 2 randomized placebo-controlled trials evaluating the efficacy of Lactobacillus rhamnosus GG, and a combination of L. rhamnosus R0011 and L. helveticus R0052, showing that moderate-to-severe gastroenteritis symptoms as primary endpoint, did not differ between probiotics or placebo. The data is important because probiotics are commonly used and prescribed in clinical practice, many times without strong evidence and producing a high economic burden. Two other examples are addressed. A systematic review of randomized placebo-controlled trial of L. reuteri DSM 17938 finding that this probiotic reduced the duration of diarrhea and hospitalization, to discuss the issue that the effect of probiotics is strain specific. In addition, the different findings of reviews and meta-analyses of probiotics in Irritable Bowel Syndrome in which a common conclusion of all of them was that adequately powered randomized controlled trials are required to better determine the species, strains and doses of probiotics, as well as the treatment duration that is most efficacious. Finally, the fact that probiotics are frequently prescribed despite lacking regulations by pharmaceutical authorities is addressed.
引用
- Schmulson M. Probiotics: To Use or Not to Use? That Is the Question. Am J Gastroenterol. 2021. PMID: 33973898. doi:10.14309/ajg.0000000000001299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。